Third Quarter Net Sales and Adjusted EBITDA Exceeded Guidance Driven by 44% OEM Growth Gross Margin Expanded 710 Basis Points Year-over-Year ...
Returned to Profitability with Net Income of $0.2M Third Consecutive Quarter of Positive Adjusted EBITDA Revenue Rises to $5.9M, with AI ...
Company plans new, confirmatory Phase 3 clinical trial of LYR-210 for treatment of chronic rhinosinusitis (CRS) without nasal polyps, on path to NDA submission – WATERTOWN, Mass., Nov. 12, 2025 (GLOBE ...
MIGDAL HAEMEK, Israel, Nov. 10, 2025 /PRNewswire/ -- Camtek Ltd. (NASDAQ: CAMT) (TASE: CAMT), today announced its financial ...
Third Quarter Net Sales and Adjusted EBITDA Exceeded Guidance Driven by 44% OEM GrowthGross Margin Expanded 710 Basis Points Year-over-YearRecent Public Offerings and Debt Restructuring Significantly ...
Mattr Corp. ("Mattr" or the "Company") (TSX: MATR) reported today its operational and financial results for the three and nine months ended September 30, 2025.